Evidence map›Paper›PMID 32651031›Full record

ReviewJournal of diabetes and its complications2020

COVID-19 in people living with diabetes: An international consensus.

A E Caballero, A Ceriello, A Misra, P Aschner, M E McDonnell, M Hassanein, L Ji, J C Mbanya, V A Fonseca

Open access · greenAbstract readReviewConsensus Statement
In one paragraph

Review in Journal of diabetes and its complications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 3 pooled it
3.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 3 syntheses or guidelines pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Optimizing Diabetes Care Through Listening to Multiple Voices.Diabetes spectrum : a publication of the American Diabetes Association · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 7 countries.

A E CaballeroBrigham and Women's Hospital, Harvard Medical School, Boston, USA. Electronic address: enrique_caballero@hms.harvard.edu.
A CerielloIRCCS MultiMedica, Milan, Italy.
A MisraFortis-C-DOC Center of Excellence for Diabetes, Metabolic Disease and Endocrinology, National Diabetes, Obesity and Cholesterol Foundation, New Dheli, India.
P AschnerSan Ignacio University Hospital, Javeriana University School of Medicine, Bogota, Colombia.
M E McDonnellBrigham and Women's Hospital, Harvard Medical School, Boston, USA.
M HassaneinDubai Hospital, Endocrine Department, Dubai Health Authority, Dubai, United Arab Emirates.
L JiPeking University People's Hospital, Peking University, Beijing, China.
J C MbanyaCentral Hospital, Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon.
V A FonsecaTulane University Medical Center, Tulane University Medical School, New Orleans, USA.
Brigham and Women's Hospital · USDubai Hospital · AEHarvard University · USHospital Universitario San Ignacio · COMultiMedica · ITNational Diabetes Obesity and Cholesterol Foundation · INPeking University People's Hospital · CNTulane University · USUniversité de Yaoundé I · CM

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI JUDD E SHELLITO · 2012 to 2026
$69.1M
NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

The COVID-19 pandemic has added an enormous toll to the existing challenge of diabetes care world-wide. A large proportion of patients with COVID-19 requiring hospitalization and/or succumbing to the disease have had diabetes and other chronic conditions as underlying risk factors. In particular, individuals belonging to racial/ethnic minorities in the U.S. and other countries have been significantly and disproportionately impacted. Multiple and complex socioeconomic factors have long played a role in increasing the risk for diabetes and now for COVID-19. Since the pandemic began, the global healthcare community has accumulated invaluable clinical experience on providing diabetes care in the setting of COVID-19. In addition, understanding of the pathophysiological mechanisms that link these two diseases is being developed. The current clinical management of diabetes is a work in progress, requiring a shift in patient-provider interaction beyond the walls of clinics and hospitals: the use of tele-medicine when feasible, innovative patient education programs, strategies to ensure medication and glucose testing availability and affordability, as well as numerous ideas on how to improve meal plans and physical activity. Notably, this worldwide experience offers us the possibility to not only prepare better for future disasters but also transform diabetes care beyond the COVID-19 era.

Indexed as

BetacoronavirusCoronavirus InfectionsCOVID-19Diabetes MellitusHumansPandemicsPneumonia, ViralSARS-CoV-2ConsensusCOVID-19COVID-19 and diabetesDiabetesDiabetes complicationsDiabetes management

Identifiers

PMID32651031
PMCPMC7336933
OpenAlexW3038672629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.